• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

ARS Pharmaceuticals, Inc. - Common Stock (NQ:SPRY)

8.560 +0.660 (+8.35%)
Streaming Delayed Price Updated: 4:00 PM EDT, Mar 26, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about ARS Pharmaceuticals, Inc. - Common Stock

< Previous 1 2 3 4 5 6 Next >
News headline image
ARS Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business Updates
November 13, 2024
From ARS Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Earnings Scheduled For November 13, 2024 ↗
November 13, 2024
 
Via Benzinga
News headline image
Insights Ahead: ARS Pharmaceuticals's Quarterly Earnings ↗
November 12, 2024
 
Via Benzinga
News headline image
ARS Pharma Jumps After Inking $145 Million Deal For Epinephrine Nasal Spray ↗
November 11, 2024
Epinephrine is usually delivered in an auto-injector. This company is the first to win approval for a nasal spray version of it. 
Via Investor's Business Daily
News headline image
ARS Pharmaceuticals Inks Licensing Pact For Neffy Allergic Reaction Treatment, Analyst Sees Further Stock Upside Despite 200% Surge In 2024 ↗
November 11, 2024
ALK and ARS Pharmaceuticals sign a deal giving ALK global rights to Neffy nasal spray outside key regions, targeting peak sales of around $400 million in anaphylaxis treatment. 
Via Benzinga
News headline image
Where ARS Pharmaceuticals Stands With Analysts ↗
October 08, 2024
 
Via Benzinga
News headline image
Analyst Ratings For ARS Pharmaceuticals ↗
September 09, 2024
 
Via Benzinga
News headline image
Looking Into ARS Pharmaceuticals's Recent Short Interest ↗
August 19, 2024
 
Via Benzinga
News headline image
ARS Pharmaceuticals Announces Exclusive Agreement with Global Allergy Leader ALK to Commercialize neffy® in Europe, Canada and Other Geographies Outside the United States
November 11, 2024
From ARS Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
ARS Pharmaceuticals Announces Conference Call and Webcasts for its Third Quarter 2024 Financial Results and Presentations at Upcoming Conferences
November 06, 2024
Third Quarter Earnings Conference Call to be Held on November 13 at 8:00 a.m. ET 
From ARS Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
ARS Pharmaceuticals Showcases Intranasal Epinephrine Data at 2024 American College of Allergy, Asthma & Immunology (ACAAI) Annual Scientific Meeting
October 24, 2024
From ARS Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
ARS Pharmaceuticals Announces U.S. Availability of neffy® (epinephrine nasal spray), the First and Only Needle-Free Treatment for Type I Allergic Reactions, Including Anaphylaxis
September 23, 2024
Visit neffy.com to “Get neffy Now” and access the comprehensive patient assistance programs available through neffyConnect 
From ARS Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
ARS Pharmaceuticals to Participate in the 2024 Cantor Global Healthcare Conference
September 10, 2024
From ARS Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
ARS Pharmaceuticals Submits sNDA to FDA for neffy® 1 mg Dose for Pediatric Patients with Type I Allergic Reactions Who Weigh 15 to 30 kg (33-66 lbs.)
September 09, 2024
From ARS Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
ARS Pharmaceuticals Launches Pre-Ordering Services for neffy® to Help Patients Access the First and Only Needle-Free Treatment for Type I Allergic Reactions, Including Anaphylaxis
September 04, 2024
From ARS Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
EURneffy (adrenaline nasal spray) Approved in the EU as the First and Only Needle-Free Emergency Treatment of Allergic Reactions (anaphylaxis)
August 26, 2024
From ARS Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Newly Approved ARS Pharmaceuticals' Needle-Free Neffy Offers Convenience Over EpiPen For Allergic Reaction, But Real-World Efficacy Questioned ↗
August 23, 2024
Neffy, a nasal spray alternative to EpiPen, offers convenience and longer shelf life but faces skepticism from allergists due to limited real-world testing and potential insurance hurdles. 
Via Benzinga
News headline image
ARS Pharmaceuticals 'Neffy Uniquely Positioned With Potential To Change Allergy Treatment Paradigm For First Time In 40 years:' Analyst ↗
August 20, 2024
"FDA recently approved ARS Pharmaceuticals' neffy nasal spray for emergency allergic reactions, offering an alternative to epinephrine autoinjectors like EpiPen. Cantor sees strong market potential and... 
Via Benzinga
News headline image
Fabrinet Posts Strong Earnings, Joins Amer Sports, Hawaiian Holdings And Other Big Stocks Moving Higher On Tuesday ↗
August 20, 2024
 
Via Benzinga
News headline image
Loar Holdings Posts Upbeat Results, Joins Nvidia, Clean Energy Fuels, Penumbra And Other Big Stocks Moving Higher On Tuesday ↗
August 13, 2024
 
Via Benzinga
News headline image
FDA Approves ARS Pharma's Once Rejected Neffy Nasal Spray Alternative To EpiPen For Emergency Allergy Treatment ↗
August 09, 2024
FDA approves ARS Pharmaceuticals' Neffy, the first nasal spray for treating severe allergic reactions and anaphylaxis. This new option offers a non-injection alternative to epinephrine autoinjectors,... 
Via Benzinga
News headline image
ARS Pharmaceuticals Receives FDA Approval of neffy® (epinephrine nasal spray), the First and Only Needle-Free Treatment for Type I Allergic Reactions, Including Anaphylaxis
August 09, 2024
From ARS Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
ARS Pharmaceuticals to Participate in the 2024 Wedbush PacGrow Healthcare Conference
August 07, 2024
From ARS Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
ARS Pharmaceuticals Provides Business Highlights and Reports Second Quarter 2024 Financial Results
August 06, 2024
From ARS Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
ARS Pharmaceuticals Announces EURneffy (adrenaline nasal spray) Recommended for Approval by CHMP for Emergency Treatment of Allergic Reactions (anaphylaxis)
June 28, 2024
From ARS Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
SPRY Stock Earnings: ARS Pharmaceuticals Meets EPS for Q1 2024 ↗
May 09, 2024
SPRY stock results show that ARS Pharmaceuticals met analyst estimates for earnings per share the first quarter of 2024. 
Via InvestorPlace
News headline image
ARS Pharmaceuticals Highlights neffy Regulatory Progress and Reports First Quarter 2024 Financial Results
May 09, 2024
From ARS Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
ARS Pharmaceuticals Submits Response for neffy® (epinephrine nasal spray) Marketing Authorization Application to EMA’s CHMP and Enters License Agreement with CSL Seqirus for Commercialization of neffy in Australia and New Zealand
April 30, 2024
From ARS Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
ARS Pharmaceuticals Submits Response to FDA Complete Response Letter for neffy® (Epinephrine Nasal Spray)
April 03, 2024
From ARS Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Top 5 Health Care Stocks That May Plunge In March ↗
March 28, 2024
As of March 28, 2024, five stocks in the health care sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions. 
Via Benzinga
< Previous 1 2 3 4 5 6 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap